H.C. Wainwright initiated coverage on SpyGlass Pharma with a new price target
$SGP
Medical/Dental Instruments
Health Care
H.C. Wainwright initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $37.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/10/2026 | $37.00 | Buy | H.C. Wainwright |
| 3/3/2026 | $42.00 | Buy | Stifel |
| 3/3/2026 | $62.00 | Buy | Jefferies |
| 3/3/2026 | $42.00 | Buy | Citigroup |
| 3/3/2026 | $42.00 | Outperform | Leerink Partners |
4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
H.C. Wainwright initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $37.00
Stifel initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $42.00
Jefferies initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $62.00
4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
4/A - SpyGlass Pharma, Inc. (0001778922) (Issuer)
4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)
Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) that demonstrated sustained intraocular pressure (IOP) control, elimination of IOP-lowering eye drops for 97% of trial participants, and improved visual performance, with a favorable safety profile.Phase 3 trials of BIM-IOL System are ongoing, with enrollment underway and full enrollment expected in 2027.Cash, cash equivalents and short-term investments expected to fund planned operations through 2028. ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- S
97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating high quality of vision, performance in line with the state-of-the-art IOLs in the control groupOverall safety results were comparable to routine cataract surgery ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for th
ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with chronic eye conditions by developing dur
10-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)
8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)